medigraphic.com
Colegio de Medicina Interna de México.

2011, Number 2

<< Back Next >>

Med Int Mex 2011; 27 (2)

Gaucher disease. A case report and review of literature

Martínez ÁI, Rivera TA, Hernández RS, Carranza MJ

Language: Spanish
References: 31
Page: 198-208
PDF size: 575.56 Kb.


ABSTRACT

The lysosomal storage diseases (LSDs) are a group of entities with a meaningful organic affectation profile and important morbid-mortality rates, which considerably affect the patients’ quality of life. At present, new lysosomal storage diseases are regularly described because their physiopathological mechanism is recognized and they are susceptible to be treated with enzyme replacement therapy.


REFERENCES

  1. Vilchez-Padilla JJ. Enfermedades del sistema nervioso por errores metabólicos congénitos. Medicine 2003;8(103):5548- 5557.

  2. Beutler E. Gaucher disease as a paradigm of current issues regarding single gene mutations of humans. Proc Natl Acad Sci 1993;90(12):5384-5390.

  3. Sidransky E. Gaucher disease and parkinsonism. Mol Genet Metab 2005;84(4):302-304.

  4. Beutler E, Gelbart T, Scott CR. Hematologically important mutations: Gaucher disease. Blood Cells Mol Dis 2005;35(3):355-364.

  5. Manger B, Menge E, Schaefer R, Haase C, et al. Gaucher disease, Fabry disease and mucopolysaccharidosis type I--how can the rheumatologist recognise these patients? J Rheumatol 2006;65(1):32,34-43.

  6. Weinreb NJ, Aggio MC, Andersson HC, Andria G, et al. Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin Hematol 2004; 41(4 Suppl 5):15-22.

  7. Jmoudiak M, Futerman AH. Gaucher disease: pathological mechanisms and modern management. Br J Haematol 2005;129(2):178-188.

  8. Michelin K, Wajner A, Bock H, Fachel A, et al. Biochemical properties of beta-glucosidase in leukocytes from patients and obligated heterozygotes for Gaucher disease carriers. Clin Chim Acta 2005;362(1-2):101-109.

  9. OMIM. Online Mendelian Inheritance in Man, OMIM. 2009 [cited 2009; Available from: http://www.ncbi.nlm.nih.gov/omim/

  10. Human Genome Mutation Database. 2009 [cited 2009; Available from: http://www.hgmd.cf.ac.uk/ac/index.php.

  11. Pastores GM, Barnett NL. Current and emerging therapies for the lysosomal storage disorders. Expert Opin Emerg Drugs 2005;10(4):891-902.

  12. Pastores GM. Gaucher Disease. GeneReviews 2006 [cited 2006 02/03/2006]; Available from: http://www.genetests.org/ query?dz=gaucher.

  13. Beutler E. Discrepancies between genotype and phenotype in hematology: an important frontier. Blood 2001;98(9):2597-2602.

  14. Accardo A, Bembi B, Pensiero S, Perissutti P. Type 3 Gaucher's disease in a three-year-old child: saccadic eye movements analysis. J AAPOS 2005;9(5): 501-503.

  15. Grabowski GA. Recent clinical progress in Gaucher disease. Curr Opin Pediatr 2005;17(4):519-524.

  16. Kaplan P, Andersson HC, Kacena KA, Yee JD. The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Arch Pediatr Adolesc Med 2006; 160(6):603-608.

  17. Mignot C, Doummar D, Maire I, De Villemeur TB. Type 2 Gaucher disease: 15 new cases and review of the literature. Brain Dev 2006;28(1):39-48.

  18. Sidransky E. Gaucher disease: complexity in a “simple” disorder. Mol Genet Metab 2004;83(1-2): 6-15.

  19. Amato D, Stachiw T, Clarke JT, Rivard GE. Gaucher disease: variability in phenotype among siblings. J Inherit Metab Dis 2004;27(5):659-669.

  20. Liou B, Kazimierczuk A, Zhang M, Scott CR, et al. Analyses of variant acid beta-glucosidases: effects of Gaucher disease mutations. J Biol Chem 2006;281(7):4242-453.

  21. Allen MJ. Pro-inflammatory cytokines and the pathogenesis of Gaucher disease: increased release of interleukin -6 e interleukin-10. QJM 1997; 90:19-25.

  22. Hollak CE. Elevated levels of M-CSF, sCD14 and IL-8 in type 1 Gaucher disease. Blood cells Mol Dis 1997;23:201-212.

  23. Derralynn H. Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease. Br J Haematol 2007;138:676-686.

  24. De Fost M. Increase incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol and Dis 2006;36:53-58.

  25. Biegstraaten M, van Schaik IN, Aerts JMFG, Hollak CEM. Non. Neuronopathic Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucheer disease patients and a systemic review of the literature. J Inherit Metab Dis 2008;31:337-349.

  26. Giraldo P, Capablo JL, Alfonso P, Latre P, et al. Manifestaciones neurológicas en pacientes con enfermedad de Gaucher y en sus familiares. Med Clin (Barc) 2008;131(5):175-179.

  27. Gan-Or Z, Giladi N, Rozovski U, Shifrin C, et al. Genotype–phenotype correlations between GBA mutations and Parkinsondisease risk and onset. Neurology 2008;70:2277-2283.

  28. Clark LN, Ross BM, Wang Y, Mejía-Santana H, et al. Mutations in the glucerebrosidase gene are associated with early-onset Parkinson disease. Neurology 2007;69:1270-1277.

  29. Pastores GM, Patel MJ, Firooznia H. Bone and joint complications related to Gaucher disease. Curr Rheumatol Rep 2000;2:175-180.

  30. Mankin HJ, Rosenthal DI, Xavier R. Gaucher disease. New approaches to an ancient disease. J Bone Joint Surg Am 2001;83-A:748-762.




2020     |     www.medigraphic.com